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Atrial Fibrillation and Risk of Cancer: A Danish Population-Based
Cohort Study
Nicklas Vinter, BMSc; Amanda M. S. Christesen, BMSc; Morten Fenger-Grøn, MSc; Anne Tjønneland, MD, PhD, DMSc;
Lars Frost, MD, PhD, DMSc
Background-—Atrial ﬁbrillation (AF) and cancer are frequent diseases worldwide. The timewise association between the diagnosis
of AF and a subsequent diagnosis of cancer may clarify whether a mutual cause exists, and may also guide clinicians about time
windows of high risk of cancer occurrence.
Methods and Results-—We conducted a population-based cohort study among 26 222 men and 28 879 women free of AF and
cancer at baseline based on the Danish Diet, Cancer and Health study. The participants were followed for the development of AF
(the Danish National Patient Registry) and subsequent cancer (the Danish Cancer Registry) until 2013. We used Cox proportional
hazard models with new-onset AF as time-dependent exposure. The men (median age 56 years) and women (median age 56 years)
were followed for medians of 16.7 and 19.6 years, respectively. AF was associated with higher risks of any type of cancer (men:
hazard ratio [HR] 1.41, 95% conﬁdence interval [CI], 1.26–1.58; women: HR 1.15, 95% CI, 1.02–1.32), and for men only, lung (HR
1.66, 95% CI, 1.19–2.30), and colorectal cancer (HR 1.37, 95% CI, 1.02–1.85). Within the initial 90 days following the diagnosis of
AF, the risks of any type of cancer (men: HR 2.89, 95% CI, 2.10–3.98; women: HR 3.72, 95% CI, 2.49–5.56), lung (men: HR 7.70,
95% CI, 4.34–13.68; women: HR 7.98, 95% CI, 3.96–16.09), and colorectal cancer (men: HR 3.35, 95% CI, 1.03–10.90; women: HR
5.91, 95% CI, 2.44–14.29) were higher for men and women.
Conclusions-—A diagnosis of AF is associated with a higher incidence rate of cancer among men and women. The cancer incidence
rate is particularly elevated within 90 days after the diagnosis of AF. ( J Am Heart Assoc. 2018;7:e009543. DOI: 10.1161/JAHA.
118.009543.)
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A trial ﬁbrillation (AF) is the most common arrhythmiaworldwide, with an increasing incidence rate and
prevalence among men and women.1 The lifetime risk is 1
in 4 according to previous studies,2,3 and more than 1 in 3
based on recent data.4 Several risk factors have been
identiﬁed, many of which are also risk factors for several
types of cancer, such as age, smoking, alcohol consumption,
and obesity.5,6 As shared risk factors link general
cardiovascular disease with cancer,6,7 the overlap between
AF and cancer may constitute a mutual cause. However, the
identiﬁcation of a mutual cause is challenging because the
association between AF and cancer seems very complex and
may include bidirectional interrelations of several factors,
many of which are not causal.8
Gaining insight into the relationship between AF and
cancer is of public health relevance. The global cancer burden
is expected to increase,9 and a recent study from Great Britain
has reported the lifetime risk to be 1 in 2 among individuals
born since 1960.10 Furthermore, the emotional distress and
economic cost of cancers are immense and most likely
rising.11 However, only 2 cohort studies have so far examined
the association between AF and the risk of subsequent
cancer. A Danish nationwide registry-based cohort study by
Ostenfeld et al suggested that occult cancer was likely to be
present at the time of the diagnosis of AF.12 Recently, Conen
et al reported an association in a population-based cohort
study of female Americans from the Women’s Health Study.13
This association needs further substantiation among both
men and women because the timewise association between
the diagnosis of AF and a subsequent diagnosis of cancer may
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clarify whether a mutual cause exists and may also guide
clinicians about time windows of high risk of cancer
occurrence.
Therefore, identifying AF as a potential risk marker for
cancer may have important public health and clinical impli-
cations. In this study, we examined the association between
new-onset AF and subsequent cancer in a large longitudinal
population-based cohort study of men and women from the
Danish Diet, Cancer, and Health cohort.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Design and Population
We conducted a population-based prospective cohort study
based on the Danish Diet, Cancer, and Health study, which
has been described in detail elsewhere.14 Brieﬂy, from 1993
to 1997, 80 996 men and 79 729 women born in the Aarhus
or Copenhagen areas were invited to participate. A diagnosis
of cancer before enrollment in the Danish Diet, Cancer, and
Health study led to exclusion. In our study, we deﬁned
baseline as the date on which the participants visited a study
center and completed a lifestyle questionnaire. Incomplete
lifestyle or diet questionnaires or a diagnosis of AF before
baseline led to exclusion. Figure 1 shows the ﬂowchart of the
exclusion process, and we followed the ﬁnal study cohort
through nationwide registries. In Denmark, all citizens are
assigned a unique 10-digit Civil Registration number that
enables cross-linking between public registers. The Civil
Registration System contains individual information on vital
statistics and migration that is updated daily.15
Exposure
Our exposure of interest was new-onset AF, and using the
Danish National Patient Registry, we retrieved this information
until any diagnosis of cancer was made (except nonmelanoma
skin cancer) or until December 31, 2013. The registry was
established in 1977 and contains prospectively registered
information from Danish hospitals on all inpatients, and after
1995, the registry also began to include outpatients.16
Diagnoses were coded in accordance with the International
Classiﬁcation of Diseases Eighth Revision (ICD-8) before 1994
Figure 1. Flowchart. AF indicates atrial ﬁbrillation; M, men; W,
women.
Clinical Perspective
What Is New?
• A new-onset diagnosis of atrial ﬁbrillation (AF) is associated
with a subsequent increased risk of being diagnosed with
cancer.
• The risk of any type of cancer, colorectal cancer, and lung
cancer is particularly high within the initial 90 days
following the diagnosis of AF.
• Metastatic cancer is likely to be present at the time of
diagnosis of AF.
What Are the Clinical Implications?
• As shared risk factors may link cardiovascular disease with
cancer, it may be worthwhile to be vigilant in patients with
AF who have risk factors for cancer such as obesity and
smoking.
• Our ﬁndings do not support recommendations for using
new-onset AF as an indication for systematic cancer
screening.
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and the Tenth Revision (ICD-10) from 1994 and onwards.
Using ﬁrst hospital contact, we identiﬁed all new-onset AF
(and atrial ﬂutter) cases irrespective of the type of AF as ICD-
8: 427.93-427.94 and ICD-10: I48. Nearly 5% of ICD-10 I48
diagnoses correspond to atrial ﬂutter.17 The positive predic-
tive value of AF (and atrial ﬂutter) diagnoses is 92% to 95% in
the Danish National Patient Registry.17,18
Outcomes
Our outcome of interest was cancer, and we followed the
participants for cancer diagnoses using the Danish Cancer
Registry until December 31, 2013. The registry was established
in 1942 and contains information on all incident cancers in the
Danish population.19 Our primary outcome was ﬁrst incident
cancer, including any type except nonmelanoma skin cancer
(ICD-10: C00-C96, except C44). Our secondary outcomes were
the most frequent cancers, which were deﬁned as the ﬁrst
diagnosed cancer being prostate cancer (ICD-10: C61), lung
cancer (ICD-10: C33-34), colorectal cancer (ICD-10: C18-20), or
breast cancer (women only, ICD-10: C50). Moreover, we
assessed the stages of the detected cancers based on the
reported TNM classiﬁcation (primary tumor, regional lymph
nodes, and distant metastasis) retrieved from the Danish
Cancer Registry. The Ann Arbor classiﬁcation of lymphomas
was unavailable beginning in 2004.
Covariates
Self-administered and interviewer-checked questionnaires
and a physical examination provided information on covari-
ates. The lifestyle and comorbidity questionnaire included
questions on hypertension, hypercholesterolemia, diabetes
mellitus, education, daily physical activity, alcohol consump-
tion, smoking habits, and for women, hormone treatment in
relation to menopause. Based on the detailed food frequency
questionnaire,20,21 we computed the Alternative Healthy
Eating Index 2010,22 and by sex, the Mediterranean Diet
Score23 and the Healthy Nordic Food Index.24 The physical
examination provided information on height and weight to
calculate body mass index.
Statistical Analysis
All analyses were sex speciﬁc. With respect to baseline
characteristics, we calculated medians with interquartile
ranges (IQR) for continuous variables, and percentages and
numbers for categorical variables.
The Aalen-Johansen estimator was used to compute
stacked cumulative incidences of cancers until 12 years after
the diagnosis of AF for the speciﬁed subtypes and other
cancers. The follow-up of 12 years after a diagnosis of AF was
chosen because it was the most appropriate period based on
assessment of the available data. The time from the diagnosis
of AF was applied as underlying timescale. The cumulative
incidence of each cancer outcome was adjusted for the
competing risk of death and the other aforementioned cancer
types.
We used Cox proportional hazards models with 95%
conﬁdence intervals (95% CIs) in which we applied age as
underlying timescale, because of its strong associations with
AF and cancer, and delayed entry at the recruitment day. As a
Cox analysis is based on comparisons between individuals
with event and individuals without event at the same time on
the timescale, using age as the underlying timescale gives the
best possible correction for age.25 Age was considered the
most important time parameter because the time of inclusion
into this population-based study was not given by a health-
related event. Death and emigration led to censoring, and in
the analyses of cancer subtypes, a ﬁrst-time cancer diagnosis
different from the subtypes of interest led to censoring as
well. We applied 2 models. Model 1 was adjusted for age
(timescale). Model 2 was adjusted for age (timescale); body
mass index, cumulated alcohol consumption, smoking dura-
tion, and tobacco consumption as continuous variables;
hypertension, hypercholesterolemia, diabetes mellitus, phys-
ical activity, and hormone treatment (women only) as
dichotomous variables; and educational level, education
length, smoking status, and Healthy Nordic Food Index as
categorical variables.
In our primary analysis, we examined the associations
between AF and risk of any cancer and cancer subtypes until
end of follow-up by using AF as a time-dependent exposure. In
the secondary analyses, we estimated the associations
between time from the diagnosis of AF and risk of any cancer
and subtypes compared with participants without AF. The
cancer risk in the periods 0 to 90 days and 0 to 365 days
after the diagnosis of AF was examined using AF as a time-
dependent indicator variable. In sensitivity analyses, we
evaluated the importance of diet with respect to development
of colorectal cancer in the periods after AF, 0 to 90 days, 0 to
365 days, and 0 days until end of follow-up, by replacing the
Healthy Nordic Food Index with the Mediterranean Diet Score
(categorical variable) or Alternative Healthy Eating Index 2010
(continuous variable) in Model 2. In the tertiary analyses, the
associations between AF and detection of localized, regional,
and metastatic cancer were examined in the aforementioned
periods. We applied AF as a time-dependent indicator variable
and adjusted as in Model 2. In these analyses, we excluded all
individuals with lymphomas beginning in 2004 since staging
information was unavailable, and if stages were missing
afterwards.
Based on Schoenfeld residuals, we tested the proportional-
hazards assumption in all the Cox models.
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All analyses were performed in Stata version 14.2 (College
Station, TX).
Ethics
The Regional Committee on Health Research Ethics in
Copenhagen and Aarhus, Denmark, and the Danish Data
Protection Agency approved The Diet, Cancer and Health
study and this present study (1-16-02-559-16). Written
informed consent was obtained from all the participants.
Results
Participants
The ﬁnal study cohort consisted of 26 222 men and 28 879
women (Figure 1), and Table 1 presents their baseline charac-
teristics. The median age of the men was 56 years at baseline,
and they were followed for a median time of 16.7 years (IQR,
14.3–17.6). During follow-up, 2776 had a diagnosis of AF. The
median age at diagnosis was 68.7 years (IQR, 64.5–73.0).
Among the women, the median age was 56 years at baseline,
and they were followed for a median time of 16.9 years (IQR,
16.2–17.7). During follow-up, 1711 had a diagnosis of AF. The
median age at diagnosis was 70.4 years (IQR, 66.3–74.9).
Approximately 22% of the men and 19% of the women had a
cancer diagnosis during follow-up, and prostate and breast
cancers were the most frequent (Table 2).
AF and Risk of Cancer
Among the men with new-onset AF, 15.0% (416/2776) had a
subsequent diagnosis of cancer, whereas 23.1% (5423/
Table 1. Baseline Characteristics
Characteristics Men (n=26 222) Women (n=28 879)
Age, median (IQR), y 56.0 (52.7–60.2) 56.2 (52.8–60.4)
BMI, median (IQR),
kg/m2
26.2 (24.1–28.5) 24.8 (22.5–27.8)
Hypertension, % (n) 14.9 (3894) 17.1 (4951)
Hypercholesterolemia,
% (n)
8.6 (2243) 6.2 (1799)
Diabetes mellitus, % (n) 2.7 (703) 1.5 (433)
Educational level, % (n)
No vocational
education
19.2 (5542) 10.0 (2621)
Low level of higher
education
31.5 (9104) 13.6 (2570)
Medium level of
higher education
38.0 (10 967) 42.3 (11 078)
High level of higher
education
11.3 (3266) 34.1 (8953)
Education length, % (n)
≤7 y 31.1 (8983) 34.6 (9075)
8–10 y 50.3 (13 528) 41.6 (10 918)
>10 y 18.6 (5368) 23.8 (6229)
Physical activity, % (n)
<30 min/d 59.1 (16 983) 62.1 (16 210)
≥30 min/d 40.9 (11 770) 37.9 (9909)
Cumulative alcohol,
median (IQR),
alcohol units
16 328 (9152–27 612) 5876 (2600–10 660)
Smoking status, % (n)
Current 32.7 (9437) 39.6 (10 393)
Former 23.5 (6773) 34.6 (9062)
Never 43.9 (12 669) 25.8 (6767)
Smoking duration,
median (IQR), y
26 (0–37) 10 (0–33)
Tobacco consumption,
median (IQR), g/d
0 (0–15) 0 (0–10)
Mediterranean diet score, % (n)
0 0.3 (87) 0.3 (66)
1 2.5 (726) 2.0 (533)
2 8.8 (2545) 6.8 (178)
3 16.4 (4732) 13.9 (3647)
4 21.1 (6099) 19.7 (5169)
5 21.7 (6271) 22.5 (5905)
6 17.3 (5000) 19.1 (5017)
7 9.0 (2601) 11.5 (3015)
8 2.5 (721) 3.7 (982)
9 0.3 (97) 0.4 (107)
Continued
Table 1. Continued
Characteristics Men (n=26 222) Women (n=28 879)
Healthy Nordic Food Index, % (n)
0 3.0 (877) 2.2 (587)
1 13.2 (3818) 12.7 (3336)
2 20.9 (6042) 20.5 (5365)
3 23.2 (6698) 22.7 (5955)
4 21.1 (6081) 21.3 (5580)
5 14.1 (4076) 15.1 (3955)
6 4.5 (1287) 5.5 (1444)
Alternative healthy
eating index,
median (IQR)
45.4 (39.2–51.7) 54.3 (47.8–60.8)
Receiving hormone
treatment, % (n)
 43.9 (12 683)
BMI indicates body mass index; IQR, interquartile range.
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23 446) of the men without a new-onset AF had a diagnosis
of cancer. Among the women with new-onset AF, 11.1% (190/
1711) had a diagnosis of cancer, whereas 19.4% (5268/
27 168) of the women without new-onset AF had a diagnosis
of cancer. Figure 2 shows the stacked cumulative incidence
of cancer among participants with new-onset AF adjusted for
the competing risk of death. During 12 years after the
diagnosis of AF, 23.3% (95% CI, 21.1–25.7) of men and 19.1%
(95% CI, 16.2–22.1) of women had a cancer diagnosis. The
median time to cancer after new-onset AF was 4.5 years for
men and 4.0 years for women. For all cancers, we noted a
higher incidence rate during the initial months after the
diagnosis of AF for both sexes (Figure 2).
Figure 3 shows the risks of any type of cancer and cancer
subtypes until the end of follow-up. Among the men, AF was
associated with any type (hazard ratio [HR] 1.41, 95% CI,
1.26–1.58), lung (HR 1.66, 95% CI, 1.19–2.30), and colorectal
cancer (HR 1.37, 95% CI, 1.02–1.85). Among the women, AF
was associated with any cancer type (HR 1.15, 95% CI, 1.02–
1.31), but not colorectal or lung cancer.
Time After the Diagnosis of AF and Risk of Cancer
Figure 3 also shows the risk of cancer in the time following
the diagnosis of AF. During the initial 90 days, the HR for any
type of cancer was 2.89 (95% CI, 2.10–4.98) in men and 3.72
(95% CI, 2.49–5.56) in women. During this period, AF was also
associated with lung (men: HR 7.70, 95% CI, 4.34–13.68;
women: HR 7.98, 95% CI, 3.96–16.09) and colorectal cancer
(men: HR 3.35, 95% CI, 1.03–10.90; women: HR 5.91, 95% CI,
2.44–14.29) for both sexes.
During the ﬁrst year, the association with any type of
cancer (men: HR 1.78, 95% CI, 1.45–2.20; women: HR 2.01,
Table 2. Numbers of Incident Cancers During Follow-Up
Men Women
Any cancer, % (n) 22.3 (5839) 18.9 (5.458)
Lung cancer, % (n) 2.7 (697) 2.4 (685)
Colorectal cancer, % (n) 3.1 (800) 2.2 (642)
Prostate cancer, % (n) 7.7 (2014) 
Breast cancer, % (n)  6.9 (1990)
Figure 2. Stacked cumulative incidence of cancer after the diagnosis of AF by sex. The individual cumulative incidence is adjusted for the
competing risk of death and other cancer subtypes. AF indicates atrial ﬁbrillation.
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95% CI, 1.51–2.67) was weaker than the association during
the initial 90 days following the diagnosis of AF for both
sexes. We also noted a lower risk of lung (men: HR 3.36, 95%
CI, 2.15–5.27; women: HR 3.35, 95% CI, 1.89–5.95),
colorectal (men: HR 2.10, 95% CI, 1.25–3.50; women: HR
3.50, 95% CI, 1.92–6.38), and other cancers (men: HR 2.08,
95% CI, 1.52–2.85; women: HR 1.64, 95% CI, 1.00–2.68)
during the ﬁrst year than during the initial 90 days.
Diet Scores and Colorectal Cancer
We adjusted for the Healthy Nordic Food Index in our main
analyses and examined the inﬂuence of adjustment for the
other diet scores in Model 2. Adjusting for different diet
scores did not change the magnitude of the HRs substantially.
AF and Detected Cancer Stages
Information on cancer stage was retrieved in 92.2% (n=5050)
of male cancer patients and 90.3% (n=4667) of female cancer
patients after excluding 364 male patients and 290 female
patients with lymphomas beginning in 2004. Table 3 shows
the sex-speciﬁc distributions of the cancer stages stratiﬁed by
Figure 3. Risk of cancer by days after a new-onset diagnosis of atrial ﬁbrillation. The estimates are adjusted as in Model 2: age (timescale), body
mass index, cumulative alcohol consumption, smoking duration, tobacco consumption, hypertension, hypercholesterolemia, diabetes mellitus,
physical activity, hormone treatment (women only), educational level, education length, smoking status, and Healthy Nordic Food Index.
Table 3. Distribution of Incident Cancer Stages During
Follow-Up*
New-Onset
Atrial Fibrillation
No Atrial
Fibrillation
Men (n=5050)
Localized, % (N) 27.1 (98) 32.9 (1542)
Regional, % (N) 13.3 (48) 20.5 (959)
Metastatic, % (N) 59.7 (216) 46.7 (2187)
Women (n=4667)
Localized, % (N) 36.8 (63) 43.4 (1954)
Regional, % (N) 25.7 (44) 30.0 (1347)
Metastatic, % (N) 37.4 (64) 26.6 (1195)
*After excluding lymphomas beginning in 2004, information on cancer stage was
retrieved for 5050 males and 4667 females with cancer.
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new-onset AF, and Table 4 gives the adjusted HRs for the
associations between time after new-onset AF and detected
cancer stages.
Among men with new-onset AF and subsequent cancer
(n=362), 59.7% of cancers were metastatic, and 27.1% were
localized. Among men without AF (n=4688) before cancer,
46.7% of cancers were metastatic, and 32.9% were localized.
A new-onset diagnosis of AF was strongly associated with
metastatic cancer within 90 days after AF (HR 3.54, 95% CI,
2.30–5.45) and somewhat weaker within 365 days after AF
(HR 2.19, 95% CI, 1.65–2.90) but persisted until the end of
follow-up (HR 1.65, 95% CI, 1.37–1.99). The tendency was
more inconsistent with respect to localized cancer. A new-
onset diagnosis of AF was not signiﬁcantly associated with
localized cancer within 90 days or within 365 days after AF,
but a diagnosis of AF was signiﬁcantly associated with an
elevated incidence of localized cancer until the end of follow-
up (HR 1.41, 95% CI, 1.15–1.73).
Among women with new-onset AF (n=171) and subsequent
cancer, 37.4% of cancers weremetastatic and 36.8% of cancers
were localized. Among women without AF (n=4496) before
cancer, 26.6% of cancers were metastatic, and 43.5% of
cancers were localized. A new-onset diagnosis of AF was
strongly associated with metastatic cancer within 90 days
after AF (HR 6.23, 95% CI, 3.43–11.29) and was somewhat
weaker within 365 days (HR 2.48, 95% CI, 1.40–4.39) and until
the end of follow-up (HR 1.68, 95% CI, 1.21–2.32). An AF
diagnosis was not statistically associated with localized cancer
within 90 days, within 365 days, or until end of follow-up.
Discussion
In this long-term prospective cohort study, we demonstrated
an association between a diagnosis of new-onset AF and a
subsequent diagnosis of any type of cancer in both sexes. The
relative cancer risk was highest within the initial 90 days after
the diagnosis of AF and remained elevated during the initial
365 days after AF for both sexes. AF was strongly associated
with metastatic cancer, particularly within 90 days after AF.
AF was also associated with a higher risk of localized cancer
during full follow-up in both sexes, although not statistically
signiﬁcant in women. The risks of colorectal and lung cancer
were highest within the initial 90 days after AF and remained
elevated during the initial 365 days for both sexes. AF was
not associated with prostate or breast cancer.
Only 2 studies have examined the association between AF
and cancer thus far.12,13 In these studies, restricted time
intervals from AF were explored, which is a methodology
different from the methods used in our study, as we explored
extended time intervals from the time of AF. The advantage of
our approach is prevention of possible selection bias because
of the most susceptible participants developing cancer early,
leaving a more resistant exposed cohort over time. Therefore,
not all of our results are directly comparable to the previous
studies. Based on the Woman’s Health Study, Conen et al
reported HRs of 1.48 (95% CI, 1.25–1.75) until the end of
follow-up, 3.54 (95% CI, 2.05–6.10) for the initial 90 days
after the diagnosis of AF, and 1.42 (95% CI, 1.18–1.71)
beyond 1 year after the diagnosis of AF.13 The fact that we
also found an association substantiates the relationship
between AF and cancer among women. Our association
within 90 days after diagnosis of AF is in accordance with the
ﬁndings of Conen et al and suggests that cancer is mainly
detected in connection with the diagnosis of AF. Conen et al
also reported a HR of 2.11 (95% CI, 1.33–3.36) for colon
cancer until the end of follow-up, but our study found that this
association was not signiﬁcant. In contrast to Conen et al, we
retrieved AF and cancer diagnoses from nationwide registries
independent of patient reporting. In the Danish registries, the
positive predictive value of AF diagnoses is 92% to 95% and of
cancer diagnoses 98%.17,18 However, in general, our results
among women are largely consistent with the Women’s
Health Study; therefore, our study extends this association to
comprise female Europeans. A Danish nationwide cohort
study by Ostenfeld et al that involved both sexes supported
an increased risk of cancer following the diagnosis of AF. This
association was particularly strong within the initial 90 days
after the diagnosis of AF.12 However, the study lacked
information on lifestyle markers, such as smoking and dietary
habits, which may have caused residual confounding.
Cancer screening programs could have inﬂuenced our
study. Organized breast cancer screening programs were
Table 4. Time After Atrial Fibrillation and Risk of Cancer
Stages During Follow-Up
Men (HR, 95% CI) Women (HR, 95% CI)
Metastatic cancer
0–90 d 3.54 (2.30–5.45) 6.23 (3.43–11.29)
0–365 d 2.19 (1.65–2.90) 2.48 (1.40–4.39)
0–end of follow-up 1.65 (1.37–1.99) 1.68 (1.21–2.32)
Regional cancer
0–90 d 0.90 (0.22–3.60) 3.58 (1.60–7.98)
0–365 d 1.05 (0.55–2.03) 1.45 (0.75–2.80)
0–end of follow-up 1.50 (1.15–1.97) 1.03 (0.81–1.31)
Localized cancer
0–90 d 2.03 (0.97–4.28) 2.18 (0.90–5.25)
0–365 d 1.06 (0.63–1.80) 1.30 (0.72–2.35)
0–end of follow-up 1.41 (1.15–1.73) 1.16 (0.93–1.44)
The estimates are adjusted as in Model 2: age (timescale), body mass index, cumulative
alcohol consumption, smoking duration, tobacco consumption, hypertension,
hypercholesterolemia, diabetes mellitus, physical activity, hormone treatment (women
only), educational level, education length, smoking status, and Healthy Nordic Food
Index. CI indicates conﬁdence interval; HR, hazard ratio.
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introduced in Copenhagen in 1991 and became nationalized
in late 2007 but were still incomplete in 2014.26 In Denmark,
unorganized and opportunistic individual-based prostate
cancer screening initiated by the patient or the doctor was
frequently performed using prostate-speciﬁc antigen.27,28
Interestingly, AF was not associated with breast or prostate
cancer in our study. Organized colorectal cancer screening
could not have inﬂuenced our study as it was introduced in
2014.
Multiple reasons may account for the timewise association
between a diagnosis of AF and a subsequent cancer
diagnosis. First, diagnostic evaluation of AF symptoms may
reveal occult cancer. If the cancer remains undetected, AF-
related antithrombotic treatment may increase the risk of
bleeding, followed by cancer detection. Anticoagulant-related
gastrointestinal bleeding has been shown to unmask cancer
during the ﬁrst month of treatment,29 which is consistent with
the increased risk of a colorectal cancer diagnosis within the
initial 90 days after AF for both sexes that was found in our
study. Antithrombotic treatment may also cause hematuria;
however, only a small percentage of patients with macro-
scopic hematuria are diagnosed with prostate cancer.30
Second, other AF-related treatments, such as amiodarone or
digoxin, may also be associated with an increased risk of
cancer,31,32 and a causal relationship between AF per se and
cancer may exist. However, both seem unlikely because of the
strong association with metastatic cancer within 90 days, the
initial sharp increase in the cumulative incidence of cancer,
and the attenuation of the HRs over time, all of which suggest
that cancer is already present at the time of the diagnosis of
AF. Our results showed an increased risk of localized cancer
during full follow-up, which may suggest a common underlying
mechanism. Chronic inﬂammation is an important part of the
initiation and maintenance of AF, in which inﬂammatory
pathways contribute to electrical and structural atrial
remodeling.33 In cancer, chronic inﬂammation promotes
carcinogenesis and tumor progression.34 Several common
risk factors, such as alcohol and obesity, may share biology
with AF and cancer because of proinﬂammatory and inﬂam-
matory causal pathways.6 Third, undiagnosed AF is common,5
and cancer symptoms may lead to diagnostic evaluations that
detect both AF and cancer. This is supported by the ﬁnding of
the high risk of metastatic cancer that is expected to be
symptomatic. Fourth, the association may be a result of
residual confounding, which may explain the long-term
association, although we adjusted for the most relevant
confounders.
Our ﬁndings may have clinical implications. In our study, a
new-onset diagnosis of AF was associated with coexistent
cancer that was probably already metastatic. Our ﬁndings do
not support recommendations for using new-onset AF as an
indication for systematic cancer screening. As shared risk
factors may link cardiovascular disease with cancer, it may
be worthwhile to be vigilant in patients with AF who have risk
factors for cancer, such as obesity and smoking. Future
studies are needed to clarify the prognostic impact of
whether a new-onset diagnosis of AF should be an impetus to
secure adherence to nationally recommended systematic
screening programs for colorectal cancer. In addition, symp-
tom-driven opportunistic screening for any cancer should be
considered.
Limitations
This study was based on the Danish Diet, Cancer, and Health
study in which 35% of the invited individuals agreed to
participate. Selection bias is unlikely to explain the observed
associations because it is doubtful that the association
between AF and cancer after enrollment depended on study
participation, and we had no loss to follow-up. Generalizability
may be an issue since invitation was restricted to individuals
born in Denmark; therefore, the vast majority of the
participants were white. We were unable to classify AF
according to duration; therefore, paroxysmal AF may have
been underreported. The number of missed AF diagnoses in
the Danish National Patient Registry is unknown. As with all
other registers, the Danish National Patient Registry is not
expected to be complete.
The exact time of the diagnosis of AF or cancer is difﬁcult
to establish because both diseases may be asymptomatic for
a long time. Residual confounding and potential changes of
baseline information during follow-up are also possible
limitations.
Conclusions
In this large prospective cohort study, we found that a new-
onset diagnosis of AF was associated with a subsequent
increased risk of being diagnosed with cancer. The risk of any
type of cancer, colorectal cancer, and lung cancer were
particularly high within the initial 90 days following the
diagnosis of AF. AF was not associated with breast or prostate
cancer. Metastatic cancer was more likely to be present at
the time of diagnosis of AF, and the detection of cancer may
have been a result of increased medical attention. An
increased association between AF and localized cancer during
full follow-up may suggest a common causal pathway. Our
ﬁndings conﬁrm and extend the previous ﬁndings in women to
involve men as well.
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